



SERIAL: dsh 3/23/06 4239-67287-05 503638 E-051-2003/0-US-04

PATENT
Attorney Reference Number 4239-67287-05

[Handwritten signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 10/537,061

Filed: June 1, 2005

Confirmation No. 2145

For: RECOMBINANT IMMUNOTOXIN AND
USE IN TREATING TUMORS

Examiner: Not yet assigned.

Art Unit: 1653

Attorney Reference No. 4239-67287-05

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed March 24, 2006

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- Supplemental Information Disclosure Statement
- Form 1449 and references cited thereon
- The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301
cc: Docketing

By

[Handwritten signature]
Susan Alpert Siegel, Rh.D.
Registration No. 43,121



MAR 27 2006

SAS: 44

03/24/06 4239-67287-05 503637 E-051-2003/0-US-04

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.**Application No.** 10/537,061**Filed:** June 1, 2005**Confirmation No.** 2145**For:** RECOMBINANT IMMUNOTOXIN AND
USE IN TREATING TUMORS**Examiner:** Not yet assigned.**Art Unit:** 1653**Attorney Reference No.** 4239-67287-05**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)Date Mailed March 24, 2006**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents and one non-English-language document. The non-English language document was cited in the European Supplementary Search Report as a category A reference. A copy of the Search Report is enclosed. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Supplemental Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. If the Commissioner determines that a fee is required, Deposit Account authority is given on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-67287-05
Application Number	10/537,061
Filing Date	June 1, 2005
First Named Inventor	Pastan
Art Unit	1653
Examiner Name	Not yet assigned.

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patente

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patente
		PCT	WO 02/32375	24 Apr 2002	Cheung
		PCT	WO 03/075846	18 Sept 2003	Cheung
		Japan	2002-253262	10 Sept 2002	Sugimoto

OTHER DOCUMENTS

	Barth, "Technology evaluation: BL22, NCI," <i>Current Opinion in Molecular Therapeutics</i> 4(1):72-75 (2002)
	Cheung et al., "Anti-Idiotypic as the Surrogate Antigen for Cloning scFv and its Fusion Proteins," <i>Hybridoma and Hybridomics</i> 21(6):433-443 (2002)
	Kreitman, et al., "Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia," <i>N. Engl. J. Medicine</i> 345(4):241-247 (July 26, 2001)
	Kreitman, "Toxin-Labeled Monoclonal Antibodies," <i>Current Pharmaceutical Biotechnology</i> 2:313-325 (2001)
	Modak, et al., "Disialoganglioside G _{D2} and antigen 8H9: Potential targets for antibody-based immunotherapy against desmoplastic small round cell tumor (DSRCT) and rhabdomyosarcoma (RMS)," <i>Proceedings of the American Association for Cancer Research</i> 40:474 (March 1999) <i>Abstract only</i>
	Onda, et al., "Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity," <i>Cancer Research</i> 61:5070-5077 (July 1, 2001).

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.